A detailed history of Man Group PLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Man Group PLC holds 37,545 shares of DNLI stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,545
Holding current value
$1.11 Million
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$14.96 - $23.22 $561,673 - $871,794
37,545 New
37,545 $871,000
Q3 2023

Nov 14, 2023

SELL
$20.63 - $30.17 $1.68 Million - $2.46 Million
-81,604 Reduced 16.15%
423,610 $8.74 Million
Q2 2023

Aug 14, 2023

BUY
$23.37 - $32.96 $11.8 Million - $16.7 Million
505,214 New
505,214 $14.9 Million
Q4 2022

Feb 14, 2023

BUY
$26.28 - $33.92 $2.85 Million - $3.68 Million
108,508 Added 315.24%
142,929 $3.97 Million
Q3 2022

Nov 14, 2022

BUY
$25.97 - $38.53 $893,913 - $1.33 Million
34,421 New
34,421 $1.06 Million
Q3 2021

Nov 15, 2021

SELL
$48.48 - $78.23 $264,894 - $427,448
-5,464 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$50.3 - $78.44 $2.67 Million - $4.16 Million
-53,061 Reduced 90.66%
5,464 $429,000
Q1 2021

May 17, 2021

SELL
$53.8 - $81.53 $2.21 Million - $3.35 Million
-41,117 Reduced 41.26%
58,525 $3.34 Million
Q4 2020

Feb 16, 2021

SELL
$36.89 - $93.56 $1.91 Million - $4.85 Million
-51,814 Reduced 34.21%
99,642 $8.35 Million
Q3 2020

Nov 16, 2020

BUY
$23.13 - $38.84 $3.5 Million - $5.88 Million
151,456 New
151,456 $5.43 Million
Q4 2018

Feb 14, 2019

SELL
$13.88 - $21.75 $145,573 - $228,114
-10,488 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$12.46 - $21.74 $130,680 - $228,009
10,488 New
10,488 $228,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.98B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.